Special Issue "Natural Products from Deep Sea 2nd Edition"

A special issue of Marine Drugs (ISSN 1660-3397). This special issue belongs to the section "Structural Studies on Marine Natural Products".

Deadline for manuscript submissions: 31 October 2024 | Viewed by 1256

Special Issue Editors

Department of Molecular Target Medicine, Aichi Medical University, Nagakute, Japan
Interests: bioactive metabolite screening from micro-organisms and plants; cellular signal transduction; development of anti-inflammatory and anticancer agents
Special Issues, Collections and Topics in MDPI journals
Associate Professor, Shenzhen Key Laboratory of Marine Bioresource and Eco-Environmental Science, College of Life Sciences and Oceanography, Shenzhen University, Shenzhen 518060, China
Interests: anti-inflammatory components; bioactive metabolites from deep-sea; marine natural products biosynthesis; green extraction

Special Issue Information

Dear Colleagues,

Along with the successful Special Issue "Natural Products from the Deep Sea”, the new Special Issue "Natural Products from the Deep Sea 2023" aims to publish useful research in the screening of pharmacologically active compounds from nature.

Many scientists have tried to isolate novel and active compounds mainly from micro-organisms, including bacteria; Streptomyces; and fungi, plants, and ordinary marine organisms, since the middle of the 20th century. However, after the long history of screening, it is becoming more difficult to find novel compounds anywhere in the world.

Until now, more than 28,600 marine natural products have been reported. However, with the development on marine natural products research, the hit rate of new compounds is also decreasing. Scientists are turning their attention to the deep sea. By 2008, almost 400 compounds were isolated from deep-sea organisms. By 2013, a further 188 new deep-sea natural products were reported. About 75% of the deep-sea-origin compounds were reported to show biological activity (i.e., 141 of 188 compounds), with almost half (i.e., 81 of 188 compounds) exhibiting potent cytotoxicity in human cancer cell lines [Scropeta et al, 2014].

In addition to the micro-organisms, there are also sponges and corals in the deep sea. An investigation of the extracts of 65 twilight-zone (50–1000 m depth) sponges, gorgonians, hard corals, and sponge-associated bacteria resulted in an extremely high hit rate (42%) of active extracts, with a hit rate for sponge and gorgonian extracts of 72% [Schupp et al, 2009 and Wright et al. 2012].

Therefore, deep-sea organisms are important sources of natural products, especially for screening of pharmacologically active compounds. In this Special Issue, I would like to bring together articles on the screening of both new chemicals and bioactive metabolites produced by deep-sea organisms. Articles concerning the timely synthesis and biotransformation of natural products from the deep sea are also welcome. This Special Issue “Natural Products from the Deep Sea” will be useful for the screening of pharmacologically active compounds from nature.

Prof. Dr. Kazuo Umezawa
Dr. Liyan Wang
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Marine Drugs is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.


  • natural products
  • deep-sea organisms
  • isolation
  • structure determination
  • synthesis
  • biotransformation
  • biological activities

Related Special Issue

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:


15 pages, 1522 KiB  
Novel Sesquiterpene and Diterpene Aminoglycosides from the Deep-Sea-Sediment Fungus Trichoderma sp. SCSIOW21
Mar. Drugs 2023, 21(1), 7; https://doi.org/10.3390/md21010007 - 22 Dec 2022
Cited by 1 | Viewed by 1049
Six new sesquiterpene aminoglycosides, trichaspside F (2) and cyclonerosides A–E (59), two new diterpene aminoglycosides, harzianosides A and B (10, 11), and three known sesquiterpenes, trichodermoside (1), cycloneran-3,7,10,11-tetraol (3), and cyclonerodiol [...] Read more.
Six new sesquiterpene aminoglycosides, trichaspside F (2) and cyclonerosides A–E (59), two new diterpene aminoglycosides, harzianosides A and B (10, 11), and three known sesquiterpenes, trichodermoside (1), cycloneran-3,7,10,11-tetraol (3), and cyclonerodiol (4), have been isolated from the n-butanol extract of Trichoderma sp. SCSIOW21 (Hypocreaceae), a deep-sea-sediment-derived fungus. The structures and relative configurations of the new compounds were determined using spectroscopic techniques and comparisons with those reported in the literature. The absolute configurations of the aglycone part of cyclonerosides A–E (59) were tentatively proposed based on optical rotation and biogenic considerations. Cyclonerosides A–E (59) represent the first glycosides of cyclonelane-type sesquiterpenes generated from Trichoderma. The NO-production-inhibitory activities were evaluated using macrophage RAW264.7 cells. Among the isolated compounds, trichaspside F (2) and cyclonerosides B–E (69) exhibited the strongest NO-production-inhibitory activities with IC50 values of 54.8, 50.7, 57.1, 42.0, and 48.0 µM, respectively, compared to the IC50 value of 30.8 µM for the positive control (quercetin). When tested for anti-fungal activities against several pathogenic fungi, none of the compounds exhibited significant activities at a concentration of 100 µM. Full article
(This article belongs to the Special Issue Natural Products from Deep Sea 2nd Edition)
Show Figures

Figure 1

Back to TopTop